

Subject Health Insurance; Coverage of Biomarker Testing

Authors Reyer

Analyst Larie Ann Pampuch (larie.pampuch@house.mn.gov)

Date March 15, 2023

## Summary

Section	Description
---------	-------------

1	<b>[62Q.473] Biomarker testing.</b>
---	-------------------------------------

**Subd. 1. Definitions.** Defines “biomarker,” “biomarker testing,” “clinical utility,” “consensus statement,” and “nationally recognized clinical practice guidelines.”

**Subd. 2. Biomarker testing; coverage required.** (a) Requires a health plan company to cover biomarker testing to diagnose, treat, manage, and monitor illness or disease if the test provides clinical utility. Provides circumstances under which clinical utility can be demonstrated.

(b) Requires coverage under this section to be provided in a manner that limits disruption of care.

(c) Clarifies that nothing in this section prohibits a health plan company from requiring a prior authorization or imposing other utilization controls when providing the coverage required by this section.

**Effective date.** This section is effective January 1, 2025.

2	<b>Biomarker testing.</b>
---	---------------------------

Requires medical assistance to cover biomarker testing and meet the requirements otherwise imposed on a health plan company under section 1.

**Effective date.** This section is effective January 1, 2025, or upon federal approval, whichever is later.